Fig. 1. Positivity for aPL (including both ACL and anti-β2-GPI) and ANA among patients treated with sodium VPA (Group A) and CBZ (Group B) before treatment initiation, as well as in age-matched healthy controls. Fisher's exact test was used to compare groups (Groups A and B vs. controls). ACL: anticardiolipin antibodies, ANA: antinuclear antibodies, anti-β2-GPI: anti-β2-glycoprotein I antibodies, aPL: antiphospholipid antibodies, CBZ: carbamazepine, VPA: valproate.